Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 53 entries
Sorted by: Best Match Show Resources per page
High-risk HPV is not associated with epithelial ovarian cancer in a Caucasian population.

Infectious agents and cancer

Ingerslev K, Hogdall E, Skovrider-Ruminski W, Schnack TH, Karlsen MA, Nedergaard L, Hogdall C, Blaakær J.
PMID: 27418945
Infect Agent Cancer. 2016 Jul 14;11:39. doi: 10.1186/s13027-016-0087-4. eCollection 2016.

BACKGROUND: High-risk human papillomavirus (HPV) has been suspected to play a role in the carcinogenesis of epithelial ovarian cancer (EOC). However, results from previous studies are conflicting. In most of these studies, the number of tissue samples was small....

Cite
Ingerslev K, Hogdall E, Skovrider-Ruminski W, et al. High-risk HPV is not associated with epithelial ovarian cancer in a Caucasian population. Infect Agent Cancer. 2016;11:39doi: 10.1186/s13027-016-0087-4.
Ingerslev, K., Hogdall, E., Skovrider-Ruminski, W., Schnack, T. H., Karlsen, M. A., Nedergaard, L., Hogdall, C., & Blaakær, J. (2016). High-risk HPV is not associated with epithelial ovarian cancer in a Caucasian population. Infectious agents and cancer, 1139. https://doi.org/10.1186/s13027-016-0087-4
Ingerslev, Kasper, et al. "High-risk HPV is not associated with epithelial ovarian cancer in a Caucasian population." Infectious agents and cancer vol. 11 (2016): 39. doi: https://doi.org/10.1186/s13027-016-0087-4
Ingerslev K, Hogdall E, Skovrider-Ruminski W, Schnack TH, Karlsen MA, Nedergaard L, Hogdall C, Blaakær J. High-risk HPV is not associated with epithelial ovarian cancer in a Caucasian population. Infect Agent Cancer. 2016 Jul 14;11:39. doi: 10.1186/s13027-016-0087-4. eCollection 2016. PMID: 27418945; PMCID: PMC4944309.
Copy Download .nbib Format: NLM
Sample handling for mass spectrometric proteomic investigations of human urine.

Proteomics. Clinical applications

Petri AL, Høgdall C, Christensen IJ, Simonsen AH, T'jampens D, Hellmann ML, Kjaer SK, Fung ET, Høgdall E.
PMID: 21136916
Proteomics Clin Appl. 2008 Sep;2(9):1184-93. doi: 10.1002/prca.200780010. Epub 2008 Jul 21.

Because of its non-invasive sample collection method, human urine is an attractive biological material both for discovering biomarkers and for use in future screening trials for different diseases. Before urine can be used for these applications, standardized protocols for...

Cite
Petri AL, Høgdall C, Christensen IJ, et al. Sample handling for mass spectrometric proteomic investigations of human urine. Proteomics Clin Appl. 2008;2(9):1184-93doi: 10.1002/prca.200780010.
Petri, A. L., Høgdall, C., Christensen, I. J., Simonsen, A. H., T'jampens, D., Hellmann, M. L., Kjaer, S. K., Fung, E. T., & Høgdall, E. (2008). Sample handling for mass spectrometric proteomic investigations of human urine. Proteomics. Clinical applications, 2(9), 1184-93. https://doi.org/10.1002/prca.200780010
Petri, Anette Lykke, et al. "Sample handling for mass spectrometric proteomic investigations of human urine." Proteomics. Clinical applications vol. 2,9 (2008): 1184-93. doi: https://doi.org/10.1002/prca.200780010
Petri AL, Høgdall C, Christensen IJ, Simonsen AH, T'jampens D, Hellmann ML, Kjaer SK, Fung ET, Høgdall E. Sample handling for mass spectrometric proteomic investigations of human urine. Proteomics Clin Appl. 2008 Sep;2(9):1184-93. doi: 10.1002/prca.200780010. Epub 2008 Jul 21. PMID: 21136916.
Copy Download .nbib Format: NLM
BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer.

Oncoimmunology

Donia M, Fagone P, Nicoletti F, Andersen RS, Høgdall E, Straten PT, Andersen MH, Svane IM.
PMID: 23264894
Oncoimmunology. 2012 Dec 01;1(9):1476-1483. doi: 10.4161/onci.21940.

In spite of the fact that they occur at high rates, the clinical responses of BRAF(V600) mutant metastatic melanoma to BRAF inhibitors are usually short-lasting, with most cases progressing within less than 8 mo. Immunomodulatory strategies initiated after progression...

Cite
Donia M, Fagone P, Nicoletti F, et al. BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology. 2012;1(9):1476-1483doi: 10.4161/onci.21940.
Donia, M., Fagone, P., Nicoletti, F., Andersen, R. S., Høgdall, E., Straten, P. T., Andersen, M. H., & Svane, I. M. (2012). BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology, 1(9), 1476-1483. https://doi.org/10.4161/onci.21940
Donia, Marco, et al. "BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer." Oncoimmunology vol. 1,9 (2012): 1476-1483. doi: https://doi.org/10.4161/onci.21940
Donia M, Fagone P, Nicoletti F, Andersen RS, Høgdall E, Straten PT, Andersen MH, Svane IM. BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology. 2012 Dec 01;1(9):1476-1483. doi: 10.4161/onci.21940. PMID: 23264894; PMCID: PMC3525603.
Copy Download .nbib Format: NLM
Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction.

Oncoimmunology

Idorn M, Olsen M, Halldórsdóttir HR, Skadborg SK, Pedersen M, Høgdall C, Høgdall E, Met Ö, Thor Straten P.
PMID: 29632724
Oncoimmunology. 2017 Dec 26;7(4):e1412029. doi: 10.1080/2162402X.2017.1412029. eCollection 2018.

Chemokines are essential mediators of cellular trafficking, interactions and tumor development. Though adoptive cell therapy (ACT) has been a tremendous success in the treatment of metastatic melanoma (MM), a major obstacle for successful ACT, is limited homing of effector...

Cite
Idorn M, Olsen M, Halldórsdóttir HR, et al. Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction. Oncoimmunology. 2017;7(4):e1412029doi: 10.1080/2162402X.2017.1412029.
Idorn, M., Olsen, M., Halldórsdóttir, H. R., Skadborg, S. K., Pedersen, M., Høgdall, C., Høgdall, E., Met, �. �., & Thor Straten, P. (2018). Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction. Oncoimmunology, 7(4), e1412029. https://doi.org/10.1080/2162402X.2017.1412029
Idorn, Manja, et al. "Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction." Oncoimmunology vol. 7,4 (2018): e1412029. doi: https://doi.org/10.1080/2162402X.2017.1412029
Idorn M, Olsen M, Halldórsdóttir HR, Skadborg SK, Pedersen M, Høgdall C, Høgdall E, Met Ö, Thor Straten P. Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction. Oncoimmunology. 2017 Dec 26;7(4):e1412029. doi: 10.1080/2162402X.2017.1412029. eCollection 2018. PMID: 29632724; PMCID: PMC5889291.
Copy Download .nbib Format: NLM
Oncomine™ Comprehensive Assay v3 vs. Oncomine™ Comprehensive Assay Plus.

Cancers

Vestergaard LK, Oliveira DNP, Poulsen TS, Høgdall CK, Høgdall EV.
PMID: 34680378
Cancers (Basel). 2021 Oct 18;13(20). doi: 10.3390/cancers13205230.

The usage of next generation sequencing in combination with targeted gene panels has enforced a better understanding of tumor compositions. The identification of key genomic biomarkers underlying a disease are crucial for diagnosis, prognosis, treatment and therapeutic responses. The...

Cite
Vestergaard LK, Oliveira DNP, Poulsen TS, et al. Oncomine™ Comprehensive Assay v3 vs. Oncomine™ Comprehensive Assay Plus. Cancers (Basel). 2021;13(20)doi: 10.3390/cancers13205230.
Vestergaard, L. K., Oliveira, D. N. P., Poulsen, T. S., Høgdall, C. K., & Høgdall, E. V. (2021). Oncomine™ Comprehensive Assay v3 vs. Oncomine™ Comprehensive Assay Plus. Cancers, 13(20), . https://doi.org/10.3390/cancers13205230
Vestergaard, Lau K, et al. "Oncomine™ Comprehensive Assay v3 vs. Oncomine™ Comprehensive Assay Plus." Cancers vol. 13,20 (2021). doi: https://doi.org/10.3390/cancers13205230
Vestergaard LK, Oliveira DNP, Poulsen TS, Høgdall CK, Høgdall EV. Oncomine™ Comprehensive Assay v3 vs. Oncomine™ Comprehensive Assay Plus. Cancers (Basel). 2021 Oct 18;13(20). doi: 10.3390/cancers13205230. PMID: 34680378; PMCID: PMC8533843.
Copy Download .nbib Format: NLM
Predictive value of the new ESGO-ESTRO-ESP endometrial cancer risk classification on survival and recurrence in the Danish population.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Ortoft G, Høgdall C, Hansen ES, Dueholm M.
PMID: 34112735
Int J Gynecol Cancer. 2021 Aug;31(8):1116-1124. doi: 10.1136/ijgc-2021-002582. Epub 2021 Jun 10.

OBJECTIVE: To compare the performance of the new ESGO-ESTRO-ESP (European Society of Gynecological Oncology-European Society for Radiotherapy & Oncology-European Society for Pathology) 2020 risk classification system with the previous 2016 risk classification in predicting survival and patterns of recurrence...

Cite
Ortoft G, Høgdall C, Hansen ES, et al. Predictive value of the new ESGO-ESTRO-ESP endometrial cancer risk classification on survival and recurrence in the Danish population. Int J Gynecol Cancer. 2021;31(8):1116-1124doi: 10.1136/ijgc-2021-002582.
Ortoft, G., Høgdall, C., Hansen, E. S., & Dueholm, M. (2021). Predictive value of the new ESGO-ESTRO-ESP endometrial cancer risk classification on survival and recurrence in the Danish population. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 31(8), 1116-1124. https://doi.org/10.1136/ijgc-2021-002582
Ortoft, Gitte, et al. "Predictive value of the new ESGO-ESTRO-ESP endometrial cancer risk classification on survival and recurrence in the Danish population." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society vol. 31,8 (2021): 1116-1124. doi: https://doi.org/10.1136/ijgc-2021-002582
Ortoft G, Høgdall C, Hansen ES, Dueholm M. Predictive value of the new ESGO-ESTRO-ESP endometrial cancer risk classification on survival and recurrence in the Danish population. Int J Gynecol Cancer. 2021 Aug;31(8):1116-1124. doi: 10.1136/ijgc-2021-002582. Epub 2021 Jun 10. PMID: 34112735.
Copy Download .nbib Format: NLM
Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer.

HGG advances

Kar SP, Considine DPC, Tyrer JP, Plummer JT, Chen S, Dezem FS, Barbeira AN, Rajagopal PS, Rosenow WT, Moreno F, Bodelon C, Chang-Claude J, Chenevix-Trench G, deFazio A, Dörk T, Ekici AB, Ewing A, Fountzilas G, Goode EL, Hartman M, Heitz F, Hillemanns P, Høgdall E, Høgdall CK, Huzarski T, Jensen A, Karlan BY, Khusnutdinova E, Kiemeney LA, Kjaer SK, Klapdor R, Köbel M, Li J, Liebrich C, May T, Olsson H, Permuth JB, Peterlongo P, Radice P, Ramus SJ, Riggan MJ, Risch HA, Saloustros E, Simard J, Szafron LM, Titus L, Thompson CL, Vierkant RA, Winham SJ, Zheng W, Doherty JA, Berchuck A, Lawrenson K, Im HK, Manichaikul AW, Pharoah PDP, Gayther SA, Schildkraut JM.
PMID: 34317694
HGG Adv. 2021 Jul 08;2(3). doi: 10.1016/j.xhgg.2021.100042. Epub 2021 Jun 16.

Familial, sequencing, and genome-wide association studies (GWASs) and genetic correlation analyses have progressively unraveled the shared or pleiotropic germline genetics of breast and ovarian cancer. In this study, we aimed to leverage this shared germline genetics to improve the...

Cite
Kar SP, Considine DPC, Tyrer JP, et al. Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. HGG Adv. 2021;2(3)doi: 10.1016/j.xhgg.2021.100042.
Kar, S. P., Considine, D. P. C., Tyrer, J. P., Plummer, J. T., Chen, S., Dezem, F. S., Barbeira, A. N., Rajagopal, P. S., Rosenow, W. T., Moreno, F., Bodelon, C., Chang-Claude, J., Chenevix-Trench, G., deFazio, A., Dörk, T., Ekici, A. B., Ewing, A., Fountzilas, G., Goode, E. L., Hartman, M., Heitz, F., Hillemanns, P., Høgdall, E., Høgdall, C. K., Huzarski, T., Jensen, A., Karlan, B. Y., Khusnutdinova, E., Kiemeney, L. A., Kjaer, S. K., Klapdor, R., Köbel, M., Li, J., Liebrich, C., May, T., Olsson, H., Permuth, J. B., Peterlongo, P., Radice, P., Ramus, S. J., Riggan, M. J., Risch, H. A., Saloustros, E., Simard, J., Szafron, L. M., Titus, L., Thompson, C. L., Vierkant, R. A., Winham, S. J., Zheng, W., Doherty, J. A., Berchuck, A., Lawrenson, K., Im, H. K., Manichaikul, A. W., Pharoah, P. D. P., Gayther, S. A., & Schildkraut, J. M. (2021). Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. HGG advances, 2(3), . https://doi.org/10.1016/j.xhgg.2021.100042
Kar, Siddhartha P, et al. "Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer." HGG advances vol. 2,3 (2021). doi: https://doi.org/10.1016/j.xhgg.2021.100042
Kar SP, Considine DPC, Tyrer JP, Plummer JT, Chen S, Dezem FS, Barbeira AN, Rajagopal PS, Rosenow WT, Moreno F, Bodelon C, Chang-Claude J, Chenevix-Trench G, deFazio A, Dörk T, Ekici AB, Ewing A, Fountzilas G, Goode EL, Hartman M, Heitz F, Hillemanns P, Høgdall E, Høgdall CK, Huzarski T, Jensen A, Karlan BY, Khusnutdinova E, Kiemeney LA, Kjaer SK, Klapdor R, Köbel M, Li J, Liebrich C, May T, Olsson H, Permuth JB, Peterlongo P, Radice P, Ramus SJ, Riggan MJ, Risch HA, Saloustros E, Simard J, Szafron LM, Titus L, Thompson CL, Vierkant RA, Winham SJ, Zheng W, Doherty JA, Berchuck A, Lawrenson K, Im HK, Manichaikul AW, Pharoah PDP, Gayther SA, Schildkraut JM. Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. HGG Adv. 2021 Jul 08;2(3). doi: 10.1016/j.xhgg.2021.100042. Epub 2021 Jun 16. PMID: 34317694; PMCID: PMC8312632.
Copy Download .nbib Format: NLM
Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer.

HGG advances

Kar SP, Considine DPC, Tyrer JP, Plummer JT, Chen S, Dezem FS, Barbeira AN, Rajagopal PS, Rosenow WT, Moreno F, Bodelon C, Chang-Claude J, Chenevix-Trench G, deFazio A, Dörk T, Ekici AB, Ewing A, Fountzilas G, Goode EL, Hartman M, Heitz F, Hillemanns P, Høgdall E, Høgdall CK, Huzarski T, Jensen A, Karlan BY, Khusnutdinova E, Kiemeney LA, Kjaer SK, Klapdor R, Köbel M, Li J, Liebrich C, May T, Olsson H, Permuth JB, Peterlongo P, Radice P, Ramus SJ, Riggan MJ, Risch HA, Saloustros E, Simard J, Szafron LM, Titus L, Thompson CL, Vierkant RA, Winham SJ, Zheng W, Doherty JA, Berchuck A, Lawrenson K, Im HK, Manichaikul AW, Pharoah PDP, Gayther SA, Schildkraut JM.
PMID: 34317694
HGG Adv. 2021 Jul 08;2(3). doi: 10.1016/j.xhgg.2021.100042. Epub 2021 Jun 16.

Familial, sequencing, and genome-wide association studies (GWASs) and genetic correlation analyses have progressively unraveled the shared or pleiotropic germline genetics of breast and ovarian cancer. In this study, we aimed to leverage this shared germline genetics to improve the...

Cite
Kar SP, Considine DPC, Tyrer JP, et al. Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. HGG Adv. 2021;2(3)doi: 10.1016/j.xhgg.2021.100042.
Kar, S. P., Considine, D. P. C., Tyrer, J. P., Plummer, J. T., Chen, S., Dezem, F. S., Barbeira, A. N., Rajagopal, P. S., Rosenow, W. T., Moreno, F., Bodelon, C., Chang-Claude, J., Chenevix-Trench, G., deFazio, A., Dörk, T., Ekici, A. B., Ewing, A., Fountzilas, G., Goode, E. L., Hartman, M., Heitz, F., Hillemanns, P., Høgdall, E., Høgdall, C. K., Huzarski, T., Jensen, A., Karlan, B. Y., Khusnutdinova, E., Kiemeney, L. A., Kjaer, S. K., Klapdor, R., Köbel, M., Li, J., Liebrich, C., May, T., Olsson, H., Permuth, J. B., Peterlongo, P., Radice, P., Ramus, S. J., Riggan, M. J., Risch, H. A., Saloustros, E., Simard, J., Szafron, L. M., Titus, L., Thompson, C. L., Vierkant, R. A., Winham, S. J., Zheng, W., Doherty, J. A., Berchuck, A., Lawrenson, K., Im, H. K., Manichaikul, A. W., Pharoah, P. D. P., Gayther, S. A., & Schildkraut, J. M. (2021). Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. HGG advances, 2(3), . https://doi.org/10.1016/j.xhgg.2021.100042
Kar, Siddhartha P, et al. "Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer." HGG advances vol. 2,3 (2021). doi: https://doi.org/10.1016/j.xhgg.2021.100042
Kar SP, Considine DPC, Tyrer JP, Plummer JT, Chen S, Dezem FS, Barbeira AN, Rajagopal PS, Rosenow WT, Moreno F, Bodelon C, Chang-Claude J, Chenevix-Trench G, deFazio A, Dörk T, Ekici AB, Ewing A, Fountzilas G, Goode EL, Hartman M, Heitz F, Hillemanns P, Høgdall E, Høgdall CK, Huzarski T, Jensen A, Karlan BY, Khusnutdinova E, Kiemeney LA, Kjaer SK, Klapdor R, Köbel M, Li J, Liebrich C, May T, Olsson H, Permuth JB, Peterlongo P, Radice P, Ramus SJ, Riggan MJ, Risch HA, Saloustros E, Simard J, Szafron LM, Titus L, Thompson CL, Vierkant RA, Winham SJ, Zheng W, Doherty JA, Berchuck A, Lawrenson K, Im HK, Manichaikul AW, Pharoah PDP, Gayther SA, Schildkraut JM. Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. HGG Adv. 2021 Jul 08;2(3). doi: 10.1016/j.xhgg.2021.100042. Epub 2021 Jun 16. PMID: 34317694; PMCID: PMC8312632.
Copy Download .nbib Format: NLM
RNA profiles reveal signatures of future health and disease in pregnancy.

Nature

Rasmussen M, Reddy M, Nolan R, Camunas-Soler J, Khodursky A, Scheller NM, Cantonwine DE, Engelbrechtsen L, Mi JD, Dutta A, Brundage T, Siddiqui F, Thao M, Gee EPS, La J, Baruch-Gravett C, Santillan MK, Deb S, Ame SM, Ali SM, Adkins M, DePristo MA, Lee M, Namsaraev E, Gybel-Brask DJ, Skibsted L, Litch JA, Santillan DA, Sazawal S, Tribe RM, Roberts JM, Jain M, Høgdall E, Holzman C, Quake SR, Elovitz MA, McElrath TF.
PMID: 34987224
Nature. 2022 Jan 05; doi: 10.1038/s41586-021-04249-w. Epub 2022 Jan 05.

Maternal morbidity and mortality continue to rise, and pre-eclampsia is a major driver of this burden

Cite
Rasmussen M, Reddy M, Nolan R, et al. RNA profiles reveal signatures of future health and disease in pregnancy. Nature. 2022;doi: 10.1038/s41586-021-04249-w.
Rasmussen, M., Reddy, M., Nolan, R., Camunas-Soler, J., Khodursky, A., Scheller, N. M., Cantonwine, D. E., Engelbrechtsen, L., Mi, J. D., Dutta, A., Brundage, T., Siddiqui, F., Thao, M., Gee, E. P. S., La, J., Baruch-Gravett, C., Santillan, M. K., Deb, S., Ame, S. M., Ali, S. M., Adkins, M., DePristo, M. A., Lee, M., Namsaraev, E., Gybel-Brask, D. J., Skibsted, L., Litch, J. A., Santillan, D. A., Sazawal, S., Tribe, R. M., Roberts, J. M., Jain, M., Høgdall, E., Holzman, C., Quake, S. R., Elovitz, M. A., & McElrath, T. F. (2022). RNA profiles reveal signatures of future health and disease in pregnancy. Nature, . https://doi.org/10.1038/s41586-021-04249-w
Rasmussen, Morten, et al. "RNA profiles reveal signatures of future health and disease in pregnancy." Nature vol. (2022). doi: https://doi.org/10.1038/s41586-021-04249-w
Rasmussen M, Reddy M, Nolan R, Camunas-Soler J, Khodursky A, Scheller NM, Cantonwine DE, Engelbrechtsen L, Mi JD, Dutta A, Brundage T, Siddiqui F, Thao M, Gee EPS, La J, Baruch-Gravett C, Santillan MK, Deb S, Ame SM, Ali SM, Adkins M, DePristo MA, Lee M, Namsaraev E, Gybel-Brask DJ, Skibsted L, Litch JA, Santillan DA, Sazawal S, Tribe RM, Roberts JM, Jain M, Høgdall E, Holzman C, Quake SR, Elovitz MA, McElrath TF. RNA profiles reveal signatures of future health and disease in pregnancy. Nature. 2022 Jan 05; doi: 10.1038/s41586-021-04249-w. Epub 2022 Jan 05. PMID: 34987224.
Copy Download .nbib Format: NLM
DNA sequencing of cytopathologically inconclusive EUS-FNA from solid pancreatic lesions suspicious for malignancy confirms EUS diagnosis.

Endoscopic ultrasound

Plougmann JI, Klausen P, Toxvaerd A, Abedi AA, Kovacevic B, Karstensen JG, Poulsen TS, Kalaitzakis E, Høgdall E, Vilmann P.
PMID: 31552911
Endosc Ultrasound. 2020 Jan-Feb;9(1):37-44. doi: 10.4103/eus.eus_36_19.

BACKGROUND AND OBJECTIVES: EUS-FNA is inconclusive in up to 10%-15% of patients with solid pancreatic lesions (SPLs). We aimed to investigate whether supplementary genetic analyses with whole-exome sequencing add diagnostic value in patients with SPLs suspicious of malignancy but...

Cite
Plougmann JI, Klausen P, Toxvaerd A, et al. DNA sequencing of cytopathologically inconclusive EUS-FNA from solid pancreatic lesions suspicious for malignancy confirms EUS diagnosis. Endosc Ultrasound. 2020;9(1):37-44doi: 10.4103/eus.eus_36_19.
Plougmann, J. I., Klausen, P., Toxvaerd, A., Abedi, A. A., Kovacevic, B., Karstensen, J. G., Poulsen, T. S., Kalaitzakis, E., Høgdall, E., & Vilmann, P. (2020). DNA sequencing of cytopathologically inconclusive EUS-FNA from solid pancreatic lesions suspicious for malignancy confirms EUS diagnosis. Endoscopic ultrasound, 9(1), 37-44. https://doi.org/10.4103/eus.eus_36_19
Plougmann, Julie Isabelle, et al. "DNA sequencing of cytopathologically inconclusive EUS-FNA from solid pancreatic lesions suspicious for malignancy confirms EUS diagnosis." Endoscopic ultrasound vol. 9,1 (2020): 37-44. doi: https://doi.org/10.4103/eus.eus_36_19
Plougmann JI, Klausen P, Toxvaerd A, Abedi AA, Kovacevic B, Karstensen JG, Poulsen TS, Kalaitzakis E, Høgdall E, Vilmann P. DNA sequencing of cytopathologically inconclusive EUS-FNA from solid pancreatic lesions suspicious for malignancy confirms EUS diagnosis. Endosc Ultrasound. 2020 Jan-Feb;9(1):37-44. doi: 10.4103/eus.eus_36_19. PMID: 31552911; PMCID: PMC7038737.
Copy Download .nbib Format: NLM
Evidence of No Association Between Human Papillomavirus and Breast Cancer.

Frontiers in oncology

Bønløkke S, Blaakær J, Steiniche T, Høgdall E, Jensen SG, Hammer A, Balslev E, Strube ML, Knakkergaard H, Lenz S.
PMID: 29938198
Front Oncol. 2018 Jun 08;8:209. doi: 10.3389/fonc.2018.00209. eCollection 2018.

BACKGROUND: Globally, breast cancer is the most frequent cancer among women. Studies reported an increased risk of breast cancer among women with prior cervical dysplasia. This study aimed to describe the prevalence of human papillomavirus (HPV) in breast cancer...

Cite
Bønløkke S, Blaakær J, Steiniche T, et al. Evidence of No Association Between Human Papillomavirus and Breast Cancer. Front Oncol. 2018;8:209doi: 10.3389/fonc.2018.00209.
Bønløkke, S., Blaakær, J., Steiniche, T., Høgdall, E., Jensen, S. G., Hammer, A., Balslev, E., Strube, M. L., Knakkergaard, H., & Lenz, S. (2018). Evidence of No Association Between Human Papillomavirus and Breast Cancer. Frontiers in oncology, 8209. https://doi.org/10.3389/fonc.2018.00209
Bønløkke, Sara, et al. "Evidence of No Association Between Human Papillomavirus and Breast Cancer." Frontiers in oncology vol. 8 (2018): 209. doi: https://doi.org/10.3389/fonc.2018.00209
Bønløkke S, Blaakær J, Steiniche T, Høgdall E, Jensen SG, Hammer A, Balslev E, Strube ML, Knakkergaard H, Lenz S. Evidence of No Association Between Human Papillomavirus and Breast Cancer. Front Oncol. 2018 Jun 08;8:209. doi: 10.3389/fonc.2018.00209. eCollection 2018. PMID: 29938198; PMCID: PMC6002490.
Copy Download .nbib Format: NLM
Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization for Low and High Throughput HER2 Genetic Testing.

International journal of breast cancer

Poulsen TS, Espersen ML, Kofoed V, Dabetic T, Høgdall E, Balslev E.
PMID: 24383005
Int J Breast Cancer. 2013;2013:368731. doi: 10.1155/2013/368731. Epub 2013 Dec 05.

The purpose was to evaluate and compare 5 different HER2 genetic assays with different characteristics that could affect the performance to analyze the human epidermal growth factor 2 (HER2) gene copy number under low and high throughput conditions. The...

Cite
Poulsen TS, Espersen ML, Kofoed V, et al. Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization for Low and High Throughput HER2 Genetic Testing. Int J Breast Cancer. 2013;2013:368731doi: 10.1155/2013/368731.
Poulsen, T. S., Espersen, M. L., Kofoed, V., Dabetic, T., Høgdall, E., & Balslev, E. (2013). Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization for Low and High Throughput HER2 Genetic Testing. International journal of breast cancer, 2013368731. https://doi.org/10.1155/2013/368731
Poulsen, Tim S, et al. "Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization for Low and High Throughput HER2 Genetic Testing." International journal of breast cancer vol. 2013 (2013): 368731. doi: https://doi.org/10.1155/2013/368731
Poulsen TS, Espersen ML, Kofoed V, Dabetic T, Høgdall E, Balslev E. Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization for Low and High Throughput HER2 Genetic Testing. Int J Breast Cancer. 2013;2013:368731. doi: 10.1155/2013/368731. Epub 2013 Dec 05. PMID: 24383005; PMCID: PMC3870126.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 53 entries